Dear Valued Customers of Quanta BioDesign, Ltd.,
During a time of significant health, social, and economic uncertainly, we want to reassure you that we are working proactively and decisively to mitigate the impact of the coronavirus disease 2019 (COVID-19) on our ability to supply you with our high-quality dPEG® reagents. These efforts are proceeding on multiple fronts:
Supply Chain
Because most of our supply chain is in the United States, we were able to minimize disruptions to our supply before the pandemic arrived here. We continue to maintain maximum reserves of critical raw materials and explore ways to enhance our storage capacity as the crisis evolves. Our hours of operations remain the same (9 AM – 5 PM EST, Monday through Friday). If these hours change as the situation evolves, we will post that information on our website.
Supporting our Employees
As always, we encourage our employees to stay home if they are ill, and are sent home if they appear ill upon arrival. In addition, we are able to relax our PTO policy to ensure that our employees feel supported.
Keeping our facility clean and safe
We have always been proud of our overall quality measures, including the cleanliness of our facility. We have increased the frequency of our cleaning and sanitization procedures, prohibited non-essential visitors to our facility, and increased sanitization measures in our receiving area.
Local, State, and Federal Guidelines
Because the dPEG® reagents that we make are critical raw materials for many clinical products, we are actively consulting with legal counsel on strategies to keep our manufacturing operations open in the event of a mandated lockdown.
As we navigate this complex and rapidly changing environment, please know that you all stay in our thoughts and prayers as we work to supply you with the dPEG® products that you need so that you can continue your important work of developing and manufacturing life-saving diagnostics and therapeutics.
Kindest Regards,
Paul D. Davis, Ph.D.
Founder, President, and CEO
Quanta BioDesign, Ltd.